Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
Holding GKOS?
Track your performance easily
GKOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$59.22 - $139.51
Previous Close$131.77
Volume815.51K
Average Volume (3M)499.75K
Market Cap
$7.24B
Enterprise Value$7.14B
Total Cash (Recent Filing)$261.66M
Total Debt (Recent Filing)$156.61M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Feb 19, 2025EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.20
Shares Outstanding54,950,459
10 Day Avg. Volume481,608
30 Day Avg. Volume499,750
Standard Deviation0.14
R-Squared0.15
Alpha0.00992
Financial Highlights & Ratios
Price to Book (P/B)10.89
Price to Sales (P/S)21.19
Price to Cash Flow (P/CF)-98.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue20.88
Enterprise Value/Gross Profit29.84
Enterprise Value/Ebitda-73.09
Forecast
1Y Price Target
$139.00Price Target Upside5.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Glaukos News
Bulls Say, Bears Say
Bulls Say
Epioxa Treatment AdvancementsGKOS disclosed positive top-line results from its second phase 3 trial for Epioxa, its next-gen treatment for keratoconus, showing a statistically significant improvement in maximum corneal curvature (Kmax) at 12 months from baseline.
IDose Uptake And Market PotentialA survey of 44 US ophthalmologists indicates healthy iDose uptake, with 86% expecting to implant iDose and procedures expected to increase significantly, supporting the analyst's above-consensus estimates.
Reimbursement And Financial PerformanceGKOS reimbursement progress continues to move in the right direction with full reimbursement for procedures and minimal out-of-pocket payments for patients.
Bears Say
Financial PerformanceThe initial launch phase of iDose has increased costs, impacting gross margin and SG&A into year-end.
Market PerformanceMixed survey results for MIGS show a decline in expected iStent W volumes by 6%, contributing to a net share loss for GKOS's iStent franchise.
Market StrategyShares are expected to take a breather near-term on gross margin headwinds and higher SG&A launch costs.
---
Ownership Overview
5.91% Insiders
40.14% Mutual Funds
1.29% Other Institutional Investors
27.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $59.22 and its highest was $139.50 in the past 12 months.
What is Glaukos’s market cap?
Currently, no data Available
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is Feb 19, 2025 which is in 106 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on Nov 04, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.478 by $0.198.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Undervalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -$0.42.
How many shares outstanding does Glaukos have?
Glaukos has 54,950,460 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.478. Following the earnings report the stock price went up 0.376%.
Which hedge fund is a major shareholder of Glaukos?
Among the largest hedge funds holding Glaukos’s share is PRIMECAP Management Co. It holds Glaukos’s shares valued at 144M.
---
Glaukos Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$139.00 (5.80% Upside)
$139.00 (5.80% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 834.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 13.8%
Last 30 Days ▲ 13.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.78%
12-Months-Change
Fundamentals
Return on Equity
-27.49%
Trailing 12-Months
Asset Growth
-3.87%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
---
GKOS Earnings Call
Q2 2024
0:00 / 0:00
---
GKOS Stock 12 Month Forecast
Average Price Target
$139.00
▲(5.80% Upside)
Technical Analysis
Best Analysts Covering GKOS
1 Year
1 Year Success Rate
16/16 ratings generated profit
1 Year Average Return
+66.66%
assigned a buy rating 20 days ago
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +66.66% per trade.
---